
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

